OBJECTIVE: Atherosclerosis is a vascular disease that involves lesion formation at sites of disturbed flow under the influence of genetic and environmental factors. Endothelial expression of adhesion molecules that enable infiltration of immune cells is important for lesion development. Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) is an adhesion and signaling receptor expressed by many cells involved in atherosclerotic lesion development. PECAM-1 transduces signals required for proinflammatory adhesion molecule expression at atherosusceptible sites; thus, it is predicted to be proatherosclerotic. PECAM-1 also inhibits inflammatory responses, on which basis it is predicted to be atheroprotective. METHODS AND RESULTS: We evaluated herein the effect of PECAM-1 deficiency on development of atherosclerosis in LDL receptor-deficient mice. We found that PECAM-1 has both proatherosclerotic and atheroprotective effects, but that the former dominate in the inner curvature of the aortic arch whereas the latter dominate in the aortic sinus, branching arteries, and descending aorta. Endothelial cell expression of PECAM-1 was sufficient for its atheroprotective effects in the aortic sinus but not in the descending aorta, where the atheroprotective effects of PECAM-1 also required its expression on bone marrow-derived cells. CONCLUSIONS: We conclude that PECAM-1 influences initiation and progression of atherosclerosis both positively and negatively, and that it does so in a site-specific manner.
OBJECTIVE:Atherosclerosis is a vascular disease that involves lesion formation at sites of disturbed flow under the influence of genetic and environmental factors. Endothelial expression of adhesion molecules that enable infiltration of immune cells is important for lesion development. Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) is an adhesion and signaling receptor expressed by many cells involved in atherosclerotic lesion development. PECAM-1 transduces signals required for proinflammatory adhesion molecule expression at atherosusceptible sites; thus, it is predicted to be proatherosclerotic. PECAM-1 also inhibits inflammatory responses, on which basis it is predicted to be atheroprotective. METHODS AND RESULTS: We evaluated herein the effect of PECAM-1 deficiency on development of atherosclerosis in LDL receptor-deficient mice. We found that PECAM-1 has both proatherosclerotic and atheroprotective effects, but that the former dominate in the inner curvature of the aortic arch whereas the latter dominate in the aortic sinus, branching arteries, and descending aorta. Endothelial cell expression of PECAM-1 was sufficient for its atheroprotective effects in the aortic sinus but not in the descending aorta, where the atheroprotective effects of PECAM-1 also required its expression on bone marrow-derived cells. CONCLUSIONS: We conclude that PECAM-1 influences initiation and progression of atherosclerosis both positively and negatively, and that it does so in a site-specific manner.
Authors: G S Duncan; D P Andrew; H Takimoto; S A Kaufman; H Yoshida; J Spellberg; J L de la Pompa; A Elia; A Wakeham; B Karan-Tamir; W A Muller; G Senaldi; M M Zukowski; T W Mak Journal: J Immunol Date: 1999-03-01 Impact factor: 5.422
Authors: Matthias Maas; Michelle Stapleton; Carmen Bergom; David L Mattson; Debra K Newman; Peter J Newman Journal: Am J Physiol Heart Circ Physiol Date: 2004-08-19 Impact factor: 4.733
Authors: ShengPeng Wang; András Iring; Boris Strilic; Julián Albarrán Juárez; Harmandeep Kaur; Kerstin Troidl; Sarah Tonack; Joachim C Burbiel; Christa E Müller; Ingrid Fleming; Jon O Lundberg; Nina Wettschureck; Stefan Offermanns Journal: J Clin Invest Date: 2015-07-13 Impact factor: 14.808
Authors: Kyoichiro Tsuchiya; Marit Westerterp; Andrew J Murphy; Vidya Subramanian; Anthony W Ferrante; Alan R Tall; Domenico Accili Journal: Circ Res Date: 2013-02-18 Impact factor: 17.367